Sophia Genetics Lands CE Mark for Hereditary Cancer Screen | GenomeWeb

NEW YORK (GenomeWeb) – Sophia Genetics announced today that its Hereditary Cancer Solution has received CE-IVD certification.

The genetic screen uses Integrated DNA Technologies' xGen Lockdown Probes to look at 27 genes relevant to breast, ovarian, and gastrointestinal hereditary cancers and includes specialized analytics developed by Sophia. The CE Mark applies to the combination of target capture technology and analytics, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.